New Cypher PMA filed
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis filed for an in-stent restenosis indication for the sirolimus-eluting stent, firm announces May 11. Data from the 384-patient SISR trial showed that patients with blockage in previously implanted bare-metal stents who received Cypher stents had a lower incidence of target vessel failure than patients who underwent brachytherapy. Brachytherapy, or radiation from within the vessel, is the only FDA-approved treatment for in-stent restenosis. Competitor Boston Scientific's Taxus paclitaxel-eluting stent also showed positive results for the indication in the Taxus V clinical trial (1"The Gray Sheet" March 20, 2006, p. 6)...
You may also be interested in...
American College Of Cardiology 2006 Meeting In Brief
Drug-eluting stent study looks at long lesions: Johnson & Johnson/Cordis claimed victory for its Cypher stent over Boston Scientific's Taxus in the treatment of long, complex lesions, based on results of its LONG DES-II trial presented at the American College of Cardiology meeting in Atlanta on March 12. Six months after randomizing 500 patients with lesions greater than 25 mm to either Cypher or Taxus, investigators at the University of Ulsan, Seoul, Korea recorded less in-stent late loss among the Cypher group (0.05 mm +0.22 mm lumen diameter loss index for Cypher, versus 0.25 mm +0.35 mm for Taxus). Investigators also recorded 71% less in-segment restenosis for the Cypher group compared to Taxus...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.